middle.news
EVE Unveils $30B Pipeline of Reformulated Sexual Health and Cardiovascular Drugs
8:32am on Tuesday 10th of March, 2026 AEDT
•
Healthcare
Read Story
EVE Unveils $30B Pipeline of Reformulated Sexual Health and Cardiovascular Drugs
8:32am on Tuesday 10th of March, 2026 AEDT
Key Points
Completed R&D on oral spray formulations for erectile dysfunction and premature ejaculation
Developed a novel dual-molecule spray combining vardenafil and dapoxetine
Reformulated apixaban anticoagulant targeting improved solubility and patient usability
Addressable global markets exceed US$30 billion across sexual health and cardiovascular therapies
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
EVE HEALTH (ASX:EVE)
OPEN ARTICLE